A weekly collection of design, data and interactive links. Design/Data viz inFORM | MIT's Dynamic Shape Display renders 3D content physically What is the safest time to drive? | New statistics show the safest and most dangerous times to drive The Latest | An automatic list of links from Twitter Sorting algorithms visualized | Video visualization of 15 different sorting algorithms Waterbear Playground | Code in ProcessingJS using just blocks Photo/Video Robot Cars | Toymaker brings robot cars to market 20 years early The Mill VFX | The Mill VFX showreel 2013 Drum machines | Greatest drum machines ever made Synth Kit | littleBits Synth Kit in collaboration with KORG Illustration Roman Muradov | Illustrations by Roman Muradov
See last week's links Have a nice weekend! @dubly and @talyellin
5 Best Consumer Service Stocks To Own For 2015: Powershares DB Us Dollar Index Bearish Fund (UDN)
PowerShares DB US Dollar Index Bearish Fund (the Fund) is a separate series of PowerShares DB US Dollar Index Trust (the Trust). The Fund�� subsidiary is DB US Dollar Index Bearish Master Fund (the Master Fund), which is a separate series of DB US Dollar Index Bearish Master Trust (the Master Trust). The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The proceeds from the offering of Shares are invested in the Master Fund.
The Master Fund invests in futures contracts (the DX Contracts) with a view to tracking the changes, whether positive or negative, in the level of the Deutsche Bank US Dollar Index (USDX) Futures Index - Excess Return (Short Index) (referred to as the Short Index or the Index) over time. The Fund earns interest income from the United States Treasury obligations and other high credit quality short-term, fixed-income securities. The Index is calculated to reflect the changes in market value over time, whether positive or negative, of short positions in DX Contracts. DX Contracts are traded through the currency markets of ICE Futures U.S. under the symbol DX. The changes in market value over time, whether positive or negative, of the DX Contracts are related to the changes, whether positive or negative, in the level of the U.S. Dollar Index (the USDX). The Index provides a general indication of the international value of the United States dollar relative to the six major world currencies (the Index Currencies), which comprise the USDX, including Euro, Japanese Yen, British Pound, Canadian Dollar, Swedish Krona and Swiss Franc.
The Fund, through its Master Fund, establishes short positions in DX Contracts with a view to tracking the changes, whether positive or negative, in the level of the Index. The performance of the Fund also is intended to reflect the excess, if any, of its Master Fund�� interest income f! rom its holdings of the United States Treasury obligations and other high credit quality short-term, fixed-income securities over the expenses of the Fund and the Master Fund. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund and the Master Fund. DB Commodity Services LLC is an indirect wholly owned subsidiary of Deutsche Bank AG. The Bank of New York Mellon serves as the administrator of the Fund and the Master Fund.v
Advisors' Opinion:- [By Brian O'Connell]
To make a contrarian play, the PowerShares DB US Dollar Index Bearish (UDN) works the opposite way: When the dollar declines, the fund fares better.
5 Best Safest Stocks To Invest In Right Now: Turkiye Garanti Bankasi AS (GARAN)
Turkiye Garanti Bankasi AS (the Bank) is a Turkey-based financial services company. The Bank provides retail, commercial, corporate and small and medium size enterprises (SME) banking, leasing, insurance, asset management and factoring services. Other operation heading under the banking segment include mainly treasury and investment banking activities as well as unallocated income and expense items. It has a network of 822 domestic branches, seven foreign branches, three representative offices abroad and 104 offices. In addition to its branches, the Bank has 100% ownership in three banks each of which is located in Amsterdam, Bucharest and Moscow. The Bank and its affiliates operate principally in Turkey, but also have operations in the Netherlands, Romania, Russia, Turkish Republic of Northern Cyprus, Malta, Luxembourg and Germany. Advisors' Opinion:- [By Ian Sayson]
Russia�� Micex Index declined, trimming its weekly gain to 2.5 percent. OAO Mechel, the nation�� biggest producer of coal for steelmakers, slumped 1.7 percent. The Borsa Istanbul National 100 Index sank 2 percent as Turkiye Garanti Bankasi AS (GARAN) led losses in lenders. Benchmark gauges in the Czech Republic and Hungary declined at least 1.2 percent.
5 Best Safest Stocks To Invest In Right Now: MEDIWARE Information Systems Inc.(MEDW)
Mediware Information Systems, Inc., together with its subsidiaries, engages in the design, development, and marketing of software solutions targeting specific processes within healthcare institutions. The company offers software systems consisting of company's proprietary application software, and third-party licensed software and hardware. It licenses, implements, and supports clinical and performance management, blood donor, and blood and biologic management products in the United States; and medication management solutions in the United States, the United Kingdom, Ireland, and South Africa. The company?s blood and biologics management solutions include HCLL Transfusion and HCLL Donor, which address blood donor recruitment, blood processing, and transfusion activities for hospitals and medical centers; BloodSafe suite of hardware and software that enable healthcare facilities to store, monitor, distribute, and track blood products; LifeTrak software for blood centers; a nd BiologiCare, a bone, tissue, and cellular product tracking software. Its medication management products comprise WORx, a pharmacy information system to manage inpatient and outpatient pharmacy operations; MediCOE, a physician order entry module; MediMAR, a nurse point-of-care administration and bedside documentation module; MediREC, which assists in achieving compliance with a Joint Commission mandate; and pharmacy management and electronic prescribing systems. The company?s performance management products include InSight software that tracks performance metrics to assist healthcare managers to manage performance. It also provides software installation and maintenance services, as well as billing and collection services to home infusion and home/durable medical equipment markets. The company markets its products primarily through its direct sales force. Mediware Information Systems, Inc. was founded in 1970 and is headquartered in Lenexa, Kansas.
Advisors' Opinion:- [By CRWE]
Mediware Information Systems, Inc. (Nasdaq:MEDW) plans to acquire the assets of Indianapolis-based Strategic Healthcare Group LLC (SHG), a leading provider of blood management consulting, education and informatics solutions.
5 Best Safest Stocks To Invest In Right Now: Array BioPharma Inc.(ARRY)
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Advisors' Opinion:- [By Dan Carroll]
Array's phase 2 study pays off big
It's tough to find a stock anywhere on the market that had as good a week as Array BioPharma (NASDAQ: ARRY ) . Shares of the biotech picked up nearly 17.8% on the week, part of a 63.5% gain year-to-date. The company's developmental drug to treat persistent allergic asthma, ARRY-502, hit the right marks in improving patient lung function in phase 2 trial results. Even better for investors, Array CEO said several other health companies have shown interest to help the company in development of ARRY-502. - [By Sean Williams]
Shareholders "nudged" Array BioPharma (NASDAQ: ARRY ) higher by nearly 18% on the week after it announced positive mid-stage data on ARRY-502, a treatment for mild to moderate persistent allergic asthma. In its mid-stage trial, ARRY-502 met its primary endpoint of improving lung function as measured by forced expiratory volume in one second, or FEV1. In the overall trial, FEV1 increased by 3.9% compared to the placebo, while a specified subset of patients in the Th2 Biomarker group saw their FEV1 jump by 6.8% relative to the placebo. ARRY-502 also met a number of secondary endpoints. Since the asthma market is a crowded field, Array also put the feelers out there that it's looking for a licensing partner to help take this experimental drug into the next stage.
- [By Keith Speights]
Breathing easier
Array BioPharma (NASDAQ: ARRY ) shares climbed nearly 18% this week. The company announced positive results from a phase 2 study of its experimental asthma drug ARRY-502.
No comments:
Post a Comment